

ABBVIE INC.

ISIN: US00287Y1091 WKN: 00287Y109 Asset Class: **Stock**

Company



2019/11/13 22:03:55

Price
86.66
USDDifference  0.25%(0.22)

Contact Details

ABBVIE INC.

Liz Shea

North Waukegan Road 1

60064-6400 North Chicago,
Illinois

Tel: +1-847-932-7900

Fax: -

Web:

<http://www.abbvie.com/>

E-mail:

liz.shea@abbvie.com

Company Profile

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2018		2017		2016	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	16,945,000,000		21,223,000,000		16,187,000,000	
Common stock capital		18,000,000		18,000,000		18,000,000
Fixed assets	-		-		-	
Equity capital of a company		-8,446,000,000		5,097,000,000		4,636,000,000
Cash and cash equivalents	7,289,000,000		9,303,000,000		5,100,000,000	
Accrued liabilities		-		-		-
Other assets	-		-		-	
Current liabilities		17,239,000,000		16,641,000,000		9,781,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		-		-		-
Different income		-		-		-
Other liabilities		-		-		-
Total assets	59,352,000,000	59,352,000,000	70,786,000,000	70,786,000,000	66,099,000,000	66,099,000,000

Balance notes

	2018	2017	2016
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	30,000	29,000	30,000
Equity ratio	-14.23%	7.20%	7.01%
Debt-equity ratio	-802.72%	1,288.78%	1,325.78%

Others

	2018	2017	2016
Tax Expense Rate	-9.43%	31.29%	24.49%

ABBVIE INC.

ISIN: US00287Y1091

WKN: 00287Y109

Asset Class: **Stock****Income statement**

	2018	2017	2016
Turnover	32,753,000,000	28,216,000,000	25,638,000,000
Net income	5,687,000,000	5,309,000,000	5,953,000,000
EBIT	4,710,560,800	7,003,752,800	7,146,057,600
Operating income before taxes	5,197,000,000	7,727,000,000	7,884,000,000
Cash Flow	13,427,000,000	9,960,000,000	7,041,000,000
Net interest income	-	-	-
Research and development expenses	10,329,000,000	4,982,000,000	4,366,000,000
Income taxes	-490,000,000	2,418,000,000	1,931,000,000
Result from investments in subsidiaries, associates and other	-	-	-
Revenues per employee	989,577	881,896	774,609

Board of Directors**Members of Management Board**

Richard A. Gonzalez	Chairman of Board of Directors
William H.L. Burnside	Member of Board of Directors
Roxanne S. Austin	Member of Board of Directors
Robert J. Alpern	Member of Board of Directors
Rebecca B. Roberts	Member of Board of Directors
Melody B. Meyer	Member of Board of Directors
Glenn F. Tilton	Member of Board of Directors
Frederick H. Waddell	Member of Board of Directors
Edward M. Liddy	Member of Board of Directors
Edward J. Rapp	Member of Board of Directors
Brett J. Hart	Member of Board of Directors
Richard A. Gonzalez	Chairman of Managing Board
Timothy J. Richmond	Member of Executive Committee
Robert A. Michael	Member of Executive Committee
Michael E. Severino, M.D.	Member of Executive Committee
Laura J. Schumacher	Member of Executive Committee
Henry O. Gosebruch	Member of Executive Committee
Carlos Alban	Member of Executive Committee
Azita Saleki-Gerhardt	Member of Executive Committee